目的 观察评价不同剂量比索诺尔联合福辛普利治疗扩张型心肌病(DCM)合并室性心律失常患者的临床效果。方 法 将90例扩张型心肌病合并室性心律失常的患者，并按照数字表法分为两组，对照组45例给予比索洛尔(5mg)和 福辛普利(10mg)，观察组45例给予比索洛尔(10mg)和福辛普利(20mg)。比较两组临床效果。结果 观察组总有效率 95.56%明显高于对照组82.22%(χ2 =4.0500，P＜0.05)，两组治疗后BNP、CRP均显著降低(P＜0.05)，观察组治疗后 BNP、CRP均低于对照组(P＜0.05)，两组治疗后LVEDV均显著升高，而LVESV、LVEDD均显著降低(P＜0.05)，且观察 组各项心功能指标均明显的优于对照组(P＜0.05)，两组治疗后室性早搏总次数、室早二联律、三联律、短阵室速 发作次数均显著降低(P＜0.05)，且观察组各项心律失常指标均明显低于对照组(P＜0.05)。结论 大剂量比索洛尔 联合福辛普利治疗DCM合并室性心律失常的临床疗效显著，可明显降低BNP、CRP指标，有效改善心功能和心律失常 状态改善预后。

Objective To evaluate the clinical effects of different doses of bisoprolol combined with fosinopril in the treatment of patients with dilated cardiomyopathy (DCM) complicated with ventricular arrhythmia. Methods Ninety patients with dilated cardiomyopathy complicated with ventricular arrhythmia were divided into two groups according to the digital table method. 45 patients in the control group were given bisoprolol (5mg) and fosinopril (10mg), and 45 patients in the observation group. Bisoprolol (10mg) and fosinopril (20mg) were administered. The clinical effects of the two groups were compared. Results The total effective rate of the observation group was 95.56%, which was significantly higher than that of the control group 82.22%, χ2 =4.0500, P<0.05). The BNP and CRP were significantly decreased after treatment (P<0.05). The BNP and CRP were observed in the observation group. Compared with the control group (P<0.05), LVEDV was significantly increased after treatment, while LVESV and LVEDD were significantly decreased (P<0.05), and the cardiac function indexes of the observation group were significantly better than the control group (P<0.05), the total number of ventricular premature beats, ventricular premature dysfunction, triple syndrome, and short ventricular tachycardia were significantly lower in the two groups (P<0.05), and the arrhythmia indexes in the observation group were significantly lower than those in the observation group. Control group (P<0.05). Conclusion High-dose bisoprolol combined with fosinopril in the treatment of DCM with ventricular arrhythmia has a significant clinical effect, can significantly reduce BNP, CRP indicators, and effectively improve cardiac function and arrhythmia status to improve prognosis.